Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by BDF Gestion

Key Points

• BDF Gestion more than doubled its Regeneron stake in the third quarter, increasing holdings by 118.8% to 3,335 shares worth approximately $2.53 million. Institutional investors collectively own 83.31% of the company.
• Analyst sentiment remains favorable, with Regeneron carrying a consensus “Moderate Buy” rating and an average price target of $845.59. UBS upgraded the stock to “buy” and raised its target to $978.
• Regeneron reported strong quarterly results, with EPS of $14.29 beating estimates by $4.13 and revenue rising 16.7% year over year to $4.29 billion. Shares recently traded at $786.56, while insiders have sold $6.5 million of stock over the past three months.

BDF Gestion raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 118.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,335 shares of the biopharmaceutical company's stock after acquiring an additional 1,811 shares during the quarter. BDF Gestion's holdings in Regeneron Pharmaceuticals were worth $2,529,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. Orbimed Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the first quarter worth approximately $11,358,000. BlackRock Inc. bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $5,682,636,000. Contravisory Investment Management Inc. bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $6,327,000. Oxbow Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $3,342,000. Finally, Deutsche Bank AG acquired a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth $323,249,000. 83.31% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research analyst reports. Leerink Partners boosted their target price on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a "market perform" rating in a research report on Monday, August 17th. Piper Sandler raised their target price on Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the company an "overweight" rating in a report on Monday. UBS Group raised Regeneron Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their target price for the company from $660.00 to $978.00 in a report on Thursday. Citigroup lifted their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a "neutral" rating in a research report on Monday, August 3rd. Finally, Zacks Research upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Monday, September 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $845.59.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Huda Zoghbi sold 800 shares of the firm's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company's stock, valued at $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the sale, the executive vice president owned 13,134 shares in the company, valued at $11,163,900. This represents a 8.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 8,093 shares of company stock valued at $6,506,845. Company insiders own 6.97% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded down $4.18 during mid-day trading on Monday, hitting $786.56. The company had a trading volume of 167,497 shares, compared to its average volume of 818,217. Regeneron Pharmaceuticals, Inc. has a 12 month low of $572.75 and a 12 month high of $859.34. The firm has a market cap of $80.98 billion, a P/E ratio of 19.43, a PEG ratio of 1.37 and a beta of 0.16. The business's 50-day simple moving average is $791.72 and its 200-day simple moving average is $721.59. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%. The firm had revenue of $4.29 billion for the quarter, compared to analyst estimates of $3.82 billion. During the same period in the previous year, the company posted $12.81 earnings per share. The company's quarterly revenue was up 16.7% compared to the same quarter last year. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 47.93 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is presently 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.